Armored Likho BusySnake Stealer, a Python-based infostealer first disclosed by Kaspersky, is actively targeting government ...

In our latest edition of new AI apps and services, we look at a nifty content utility, a simple trip planner, and more!

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

NuML Studio is optimized for Windows and provides a "ready-to-use" version that does not require users to install Python or ...

NEW YORK, NY / ACCESS Newswire / May 17, 2026 / Tempo Mails, a digital service developed by Tech Digital Labs, has announced the launch of its Free Temporary Email Generator, a browser-based and ...

In my Boston Globe review of Louise Erdrich’s 2016 novel “LaRose,” I described her as “an artist of the liminal.” “Python’s Kiss,” Erdrich’s new collection of stories written over 20 years, testifies ...

Email signature generator EmailSignatures lets you create polished, professional email signatures in minutes. More than simply bolding your name, you can add your company’s logo, your social links — ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

If a hacker or scammer has access to your email, every account connected to it is at risk. We show you how to protect yourself fast. I review privacy tools like hardware security keys, password ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...